| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Operating activities: | ||||||||
Net loss | ||||||||
-19,551 | -19,481 | -21,961 | -24,639 | -20,219 | -21,186 | -17,406 | -12,348 | -10,760 |
Reconciliation of net loss to net cash used in operating activities: | ||||||||
Depreciation and amortization | ||||||||
369 | 336 | 340 | 331 | 293 | 271 | 194 | 179 | 156 |
Equity-based compensation | ||||||||
2,725 | 2,231 | 2,909 | 2,400 | 2,528 | 2,405 | 3,822 | 503 | 234 |
Amortization of debt discount | ||||||||
173 | - | - | - | - | - | - | - | - |
Non-cash interest expense | ||||||||
173 | -37 | 12 | 13 | 12 | 17 | 12 | 12 | 21 |
Change in fair value of warrant liability | ||||||||
- | - | - | - | -252 | - | - | - | - |
Fair Value Adjustment of Warrants | ||||||||
- | - | - | - | - | - | - | -1 | 350 |
Changes in: | ||||||||
Prepaid expenses and other assets | ||||||||
1,627 | 221 | -141 | -685 | 2,486 | -510 | 253 | -32 | 249 |
Accounts payable | ||||||||
-792 | 453 | -1,260 | 252 | -129 | 1,010 | -820 | 870 | 777 |
Accrued expense and other liabilities | ||||||||
631 | 468 | 2,131 | 1,293 | -2,543 | 2,415 | 1,712 | 581 | 13 |
Net cash used in operating activities | ||||||||
-17,899 | -15,651 | -17,688 | -19,665 | -22,796 | -14,137 | -12,533 | -10,172 | -9,458 |
Investing activities: | ||||||||
Purchase of property and equipment | ||||||||
1,075 | 998 | 719 | 743 | 1,126 | 1,059 | 1,013 | 652 | 278 |
Net cash and restricted cash used in investing activities | ||||||||
-1,075 | -998 | -719 | -743 | -1,126 | -1,059 | -1,013 | -652 | -278 |
Financing activities: | ||||||||
Proceeds from preferred stock financing, net of issuance costs | ||||||||
- | - | - | - | - | 2 | -8 | 29,813 | 70,925 |
Proceeds from exercise of stock options | ||||||||
1,561 | 92 | 406 | 72 | 60 | 30 | 84 | 4 | 2 |
Payments related to capital lease | ||||||||
22 | 22 | 22 | 22 | 25 | 27 | 27 | 25 | 26 |
Issuance of common stock, net of issuance costs | ||||||||
- | 0 | -661 | -1,021 | 69,443 | 0 | 0 | 0 | 0 |
Settlement of derivative liability | ||||||||
- | 0 | 0 | 0 | 300 | 0 | 0 | 0 | 0 |
Net cash provided by financing activities | ||||||||
1,539 | 6,712 | -277 | -971 | 69,178 | -1,353 | -408 | 29,767 | 70,901 |
Net (decrease) increase in cash, cash equivalents, and restricted cash | ||||||||
-17,435 | -9,933 | -18,684 | -21,379 | 45,256 | -16,565 | -13,954 | 18,943 | 61,165 |
Supplemental cash flow information | ||||||||
Interest paid | ||||||||
342 | 142 | 246 | 248 | 245 | 243 | 231 | 241 | 228 |
Supplemental disclosure of non-cash investing and financing activities | ||||||||
Vesting of restricted shares | ||||||||
3 | 45 | 46 | 301 | 325 | 573 | 809 | 555 | 158 |
Reclassification of warrants to additional paid-in capital | ||||||||
- | 0 | 0 | 0 | 871 | 0 | 0 | 0 | 0 |
Conversion of preferred stock to common stock upon closing of the initial public offering | ||||||||
- | 0 | 0 | 0 | 153,226 | 0 | 0 | 0 | 0 |
Deferred Offering Costs Incurred But Not Yet Paid | ||||||||
- | - | - | - | - | - | - | - | 0 |
Purchase of property and equipment in accounts payable and accrued expenses | ||||||||
- | 286 | -463 | 381 | 181 | 550 | -30 | -283 | 367 |
Initial public offering costs incurred but unpaid at period end | ||||||||
- | - | -661 | -378 | 1,039 | - | - | - | - |